Sandoz opens advanced device development center in Cambridge to enhance drug delivery

Sandoz has opened a state-of-the-art Device Development Center in Cambridge, UK, to enhance its drug-device combination products.

The Significance of the Center

The CEO of Sandoz emphasized the significance of the center in establishing a world-class organization focused on medical device and drug-device combination development.

Research in Cambridge

The research conducted in Cambridge will play a crucial role in expanding access to biosimilar and complex generic medicines globally.

The establishment of the center is part of Sandoz's strategy to invest in talent and innovation, and it is expected to streamline technology transfer and enhance operational efficiency.

Sandoz's Commitment

Sandoz, a subsidiary of Novartis, is a global leader in generic and biosimilar medicines, with a mission to pioneer access for patients.

The company reported impressive financial results in 2023, enabling continued investment in research and development.

The New Device Development Center

The new Device Development Center in Cambridge reflects Sandoz's commitment to enhancing patient access to high-quality medicines and driving advancements in drug delivery technologies.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings